AMO: limited recall of Healon D

Article

Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

AMO has already notified customers who are in possession of Healon D from the batch in question. The rest of the lot has been removed from AMO's inventory, and AMO is planning to notify the FDA.

According to the manufacturers, the adverse events - ocular inflammation at one day postoperatively - are restricted to a single batch of Healon D. No such reactions have been reported in Europe, and no other AMO viscoelastic products have been affected.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.